{"id":52690,"date":"2026-01-04T14:20:36","date_gmt":"2026-01-04T06:20:36","guid":{"rendered":"https:\/\/flcube.com\/?p=52690"},"modified":"2026-01-04T14:20:37","modified_gmt":"2026-01-04T06:20:37","slug":"tarlatamab-enters-china-via-hainan-pilot-zone-as-first-sclc-immunotherapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52690","title":{"rendered":"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy"},"content":{"rendered":"\n<p><strong>Ruijin Hospital Hainan Boao Research Hospital<\/strong> (Ruijin Hainan Hospital) successfully introduced <strong>Tarlatamab for Injection<\/strong>, making it the <strong>first medical institution in China<\/strong> to provide access to this global innovative <strong>DLL3\u2011targeted T\u2011cell engager (TCE) therapy<\/strong> for <strong>small cell lung cancer (SCLC)<\/strong>. The introduction leverages the &#8220;pioneering trial&#8221; policies of the <strong>Lecheng Pilot Zone<\/strong> in Hainan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-points\">Key Points<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Tarlatamab for Injection<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Amgen (originally); BeiGene collaboration for China<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>DLL3 x CD3 T\u2011cell engager (TCE)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Small cell lung cancer (SCLC)<\/td><\/tr><tr><td><strong>Access Point<\/strong><\/td><td>Ruijin Hainan Hospital (Hainan Boao Research Hospital)<\/td><\/tr><tr><td><strong>Policy Leveraged<\/strong><\/td><td>Lecheng Pilot Zone &#8220;pioneering trial&#8221; policy<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First China accessibility<\/strong> for Tarlatamab<\/td><\/tr><tr><td><strong>Global Approval<\/strong><\/td><td>Approved in US, Japan, UK<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-tarlatamab\">Drug Profile: Tarlatamab<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovative Design<\/strong>: Bispecific antibody simultaneously binding <strong>DLL3 on tumor cells<\/strong> and <strong>CD3 on T\u2011cells<\/strong>, activating polyclonal T\u2011cell response<\/li>\n\n\n\n<li><strong>Clinical Value<\/strong>: Addresses high unmet need in relapsed\/refractory SCLC where standard therapies show limited efficacy<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Intravenous infusion in hospital setting with monitoring<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Cytokine release syndrome (CRS) and neurotoxicity managed via established TCE protocols<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-china-sclc-market-context\">China SCLC Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China Data<\/th><\/tr><\/thead><tbody><tr><td><strong>Annual SCLC incidence<\/strong><\/td><td>~150,000\u2011180,000 new cases (2025)<\/td><\/tr><tr><td><strong>% of all lung cancers<\/strong><\/td><td>13\u201115%<\/td><\/tr><tr><td><strong>5\u2011year survival rate<\/strong><\/td><td>&lt;7% for extensive\u2011stage disease<\/td><\/tr><tr><td><strong>Current 2L+ options<\/strong><\/td><td>Topotecan, lurbinectedin (limited access)<\/td><\/tr><tr><td><strong>Target population for Tarlatamab<\/strong><\/td><td>~40,000\u201150,000 relapsed\/refractory patients<\/td><\/tr><tr><td><strong>Market potential<\/strong><\/td><td>\u00a53\u20114\u202fbillion (US$420\u2011560\u202fmillion) by 2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-policy-advantage-lecheng-pilot-zone\">Policy Advantage: Lecheng Pilot Zone<\/h2>\n\n\n\n<p>The <strong>Lecheng International Medical Tourism Pilot Zone<\/strong> allows <strong>expedited import<\/strong> of innovative drugs approved overseas but not yet available in mainland China. Key benefits include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Review Timeline<\/strong>: 3\u20116 months vs. 12\u201118 months standard NMPA approval<\/li>\n\n\n\n<li><strong>Patient Access<\/strong>: Enables treatment of <strong>urgent medical needs<\/strong> while China NDA review is pending<\/li>\n\n\n\n<li><strong>Real\u2011World Evidence<\/strong>: Data generated can support <strong>future NMPA registration<\/strong><\/li>\n\n\n\n<li><strong>Reimbursement<\/strong>: Private insurance coverage available; supports commercial preview<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-status-amp-china-pathway\">Global Status &amp; China Pathway<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Approval<\/strong>: <strong>May\u202f2025<\/strong> (accelerated approval for SCLC)<\/li>\n\n\n\n<li><strong>Japan Approval<\/strong>: <strong>October\u202f2025<\/strong><\/li>\n\n\n\n<li><strong>UK Approval<\/strong>: <strong>December\u202f2025<\/strong><\/li>\n\n\n\n<li><strong>China NDA<\/strong>: BeiGene (partner) submitted NDA in <strong>Q3\u202f2025<\/strong>; Priority Review granted<\/li>\n\n\n\n<li><strong>Commercial Launch<\/strong>: Expected <strong>mid\u20112026<\/strong> in mainland China; Hainan access provides <strong>6\u2011month head start<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<p><strong>BeiGene Collaboration<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Oncology Partnership<\/strong> with Amgen includes co\u2011development and commercialization of Tarlatamab in China<\/li>\n\n\n\n<li><strong>BeiGene<\/strong> leads regulatory filing and commercialization; <strong>Ruijin Hainan Hospital<\/strong> serves as early access center<\/li>\n\n\n\n<li><strong>Revenue Share<\/strong>: BeiGene retains majority of China profits; Amgen receives milestones and royalties<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding Tarlatamab\u2019s commercial trajectory, market penetration, and regulatory timeline in China. Actual results may differ due to competitive responses, reimbursement negotiations, and safety profile evolution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52693,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,185,91,16,28,127,2790],"class_list":["post-52690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-amgen","tag-beigene","tag-boao-lecheng-pilot-zone","tag-cancer","tag-multi-specific-antibodies","tag-ruijin-hospital","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making it the first medical institution in China to provide access to this global innovative DLL3\u2011targeted T\u2011cell engager (TCE) therapy for small cell lung cancer (SCLC). The introduction leverages the &quot;pioneering trial&quot; policies of the Lecheng Pilot Zone in Hainan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52690\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy\" \/>\n<meta property=\"og:description\" content=\"Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making it the first medical institution in China to provide access to this global innovative DLL3\u2011targeted T\u2011cell engager (TCE) therapy for small cell lung cancer (SCLC). The introduction leverages the &quot;pioneering trial&quot; policies of the Lecheng Pilot Zone in Hainan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52690\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-04T06:20:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-04T06:20:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy\",\"datePublished\":\"2026-01-04T06:20:36+00:00\",\"dateModified\":\"2026-01-04T06:20:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690\"},\"wordCount\":425,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0402.webp\",\"keywords\":[\"Amgen\",\"BeiGene\",\"Boao Lecheng pilot zone\",\"Cancer\",\"Multi-specific antibodies\",\"Ruijin Hospital\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52690#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52690\",\"name\":\"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0402.webp\",\"datePublished\":\"2026-01-04T06:20:36+00:00\",\"dateModified\":\"2026-01-04T06:20:37+00:00\",\"description\":\"Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making it the first medical institution in China to provide access to this global innovative DLL3\u2011targeted T\u2011cell engager (TCE) therapy for small cell lung cancer (SCLC). The introduction leverages the \\\"pioneering trial\\\" policies of the Lecheng Pilot Zone in Hainan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52690\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52690#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy - Insight, China&#039;s Pharmaceutical Industry","description":"Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making it the first medical institution in China to provide access to this global innovative DLL3\u2011targeted T\u2011cell engager (TCE) therapy for small cell lung cancer (SCLC). The introduction leverages the \"pioneering trial\" policies of the Lecheng Pilot Zone in Hainan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52690","og_locale":"en_US","og_type":"article","og_title":"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy","og_description":"Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making it the first medical institution in China to provide access to this global innovative DLL3\u2011targeted T\u2011cell engager (TCE) therapy for small cell lung cancer (SCLC). The introduction leverages the \"pioneering trial\" policies of the Lecheng Pilot Zone in Hainan.","og_url":"https:\/\/flcube.com\/?p=52690","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-04T06:20:36+00:00","article_modified_time":"2026-01-04T06:20:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52690#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52690"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy","datePublished":"2026-01-04T06:20:36+00:00","dateModified":"2026-01-04T06:20:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52690"},"wordCount":425,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52690#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0402.webp","keywords":["Amgen","BeiGene","Boao Lecheng pilot zone","Cancer","Multi-specific antibodies","Ruijin Hospital","T cell engager"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52690#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52690","url":"https:\/\/flcube.com\/?p=52690","name":"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52690#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52690#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0402.webp","datePublished":"2026-01-04T06:20:36+00:00","dateModified":"2026-01-04T06:20:37+00:00","description":"Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making it the first medical institution in China to provide access to this global innovative DLL3\u2011targeted T\u2011cell engager (TCE) therapy for small cell lung cancer (SCLC). The introduction leverages the \"pioneering trial\" policies of the Lecheng Pilot Zone in Hainan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52690#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52690"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52690#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0402.webp","width":1080,"height":608,"caption":"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52690#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52690"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52690\/revisions"}],"predecessor-version":[{"id":52694,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52690\/revisions\/52694"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52693"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}